At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 141 enrolled
Drug / intervention
PF-06881894 by on-body injector +1 morecombination
Likely dose
PF-06881894 by on-body injector 6 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 1, OPEN-LABEL, RANDOMIZED, SINGLE DOSE, 2-WAY CROSSOVER STUDY ASSESSING PHARMACOKINETIC COMPARABILITY OF TWO PF-06881894 PRESENTATIONS, ON-BODY INJECTOR AND PREFILLED SYRINGE, IN HEALTHY PARTICIPANTS
In Brief
A Phase 1 clinical trial evaluating PF-06881894 by on-body injector and PF-06881894 by prefilled syringe for Healthy Volunteers. Completed, enrolled 141 participants across 4 sites.
Detailed Summary
This will be an open-label, randomized, 2-treatment, 2-period, crossover single-dose study in approximately 134 healthy adult participants. Participants will be randomized into 2 sequences of treatment as described in the following table of Intervention Groups and Duration.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedJan 2022
Enrollment StartFeb 2022
Primary CompletionAug 2022
TodayJul 2026
First PostedJan 18, 2022
Enrollment StartFeb 10, 2022
Primary CompletionAug 10, 2022
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 4.5 years ago
Interventions
PF-06881894 by on-body injectorcombination
PF-06881894 given by on-body injector (OBI), 6 mg administered as a single SC injection
PF-06881894 by prefilled syringecombination
PF-06881894 given by prefilled syringe (PFS), 6 mg administered as a single SC injection